Kornimate/medical-research-clean huggingface dataset:
oriental research alliance of acute ischemic stroke given endovascular treatment

Conditions: Ischemic Stroke

Summary: to determine the safety and efficacy of in situ ischemic postconditioning immediately after successful reperfusion in ais patients underwnet evt.

for acute ischemic stroke (ais) patients with large vessel occlusion in the anterior circulation receieved successful reperfusion, in situ ischemic postconditioning (isipc) was performed immediately after successful reperfusion with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation.

Eligibility criteria:
inclusion criteria: 1. adult (age ≥ 18 to 95 years) patients with an occlusion of the internal carotid artery or m1 or m2 segment of the middle cerebral artery,; 2. patients with a score of at least 6 on the national institutes of health stroke scale (nihss) at admission and a score of 0 or 1 on the modified rankin scale before the onset of stroke; 3. patients with a score of at least 6 on the alberta stroke program early ct score (aspects) value; 4. baseline multimodal-ct imaging, including ncct, cta and ctp, performed at the trial-site hospital 5. the modified thrombolysis in cerebral infarction (mtici) scale 2b to 3 achieved in the infarct-related artery after the last thrombectomy attempt exclusion criteria: 1. stoke of large artery atherosclerotic origin or other determined factors (such as dissection) or tandem occlusion; 2. patients underwent rescue angioplasty or stenting after thrombectomy

Keywords: acute ischemic stroke thrombectomy thrombolysis outcome
mylife mystyle evaluation project

Conditions: Unsafe Sex

Summary: the purpose of the mylife mystyle evaluation project is to determine whether the mylife mystyle group-level intervention reduces hiv sexual-risk behaviors among 18- to 29-year-old african american men who have sex with men (msm). specifically, the project will test whether participants of the mylife mystyle program will report at least a 15% absolute decrease in frequency of unprotected anal sex with male partners at three and six months post-intervention compared with the wait-list control participants.

in los angeles county, as well as nationally, the primary mode of hiv transmission for african american men is sexual contact with another man. according to national data from 45 states with name-based hiv surveillance in 2006, the majority of all new hiv infections among african american males were associated with sex with other men. the disproportionate impact of hiv in aamsm in los angeles county is also observed in provisional hiv surveillance data. between 2002 and 2004, aamsm composed 16.3% of the new hiv diagnoses among males in los angeles county, with an average annual hiv diagnosis rate 2.0 and 2.5 times greater than the rates of new hiv diagnosis for white and latino msm, respectively. in addition to demonstrating the highest hiv prevalence and incidence estimates, aamsm also had the highest proportion of previously unrecognized hiv infection (67%) compared with all other racial/ethnic groups. given significant and continuing disparities in hiv infection among african americans in the united states, and specifically among aamsm, more intervention programs must be planned, implemented, and tested in order to reduce the heavy toll of hiv/aids in this population. components of these intervention programs must be culturally competent and should include promotion of hiv counseling and testing to reduce the high prevalence of unrecognized hiv infection in aamsm. interventions should also take into consideration the many co-factors that may hinder aamsm from addressing their hiv risk such as racism, poverty, stigma, and homophobia. the mylife mystyle evaluation project aims to implement and evaluate the efficacy of a "homegrown" group-level intervention to reduce hiv risk (unprotected anal sex with male partners) among young african american msm in los angeles county, ca.

Eligibility criteria:
inclusion criteria: * identify as african american or black * identify as male * age 18 to 29 years * reside within los angeles county * self-reported anal sex with a male partner in the past 12 months * has not participated in an hiv prevention intervention in the past 3 months * able to complete acasi and mylife sessions in english exclusion criteria: * identify as a transgender female * plan to move out of los angeles county before the end of their follow-up period (within 7 months)

Keywords: gay men african american males unprotected anal sex hiv risk behavioral intervention group-level intervention
safety and tolerance study of alpha-lactalbumin enriched and probiotic-supplemented infant formula in infants with colic

Conditions: Growth; Colic

Summary: the purpose of this study is to evaluate the nutritional adequacy, the digestive tolerance and the effect on colic of an alpha-lactalbumin-enriched and probiotic-supplemented infant formula.

this double-blind, placebo-controlled study was undertaken with 66 healthy infants with colic, aged 3 weeks to 3 months, fed a month either with the experimental formula (ef) or with the control formula (cf) and evaluated for efficacy and safety parameters at days 15 and 30. both parents provided informed written consent.

Eligibility criteria:
inclusion criteria: * healthy term infants with a gestational age ranging from 37 to 42 weeks * non breastfed children * infants with normal growth * infants presenting colic defined as crying periods at least 3 hours per days, 3 days per weeks, for more than 3 weeks * these crying periods could be associated with other digestive troubles(gas, abdominal distensions, regurgitations) * apgar score \> 5 to 7 minutes exclusion criteria: * infants with severe regurgitations * newborn currently participating in another trial * infants presenting a metabolic, nervous or organic disease able to interfere with the study * infants presenting lactose intolerance * evidence of protein cow's milk allergy * mother who wants to keep breasfeeding

Keywords: infant formula alpha-lactalbumin protein composition colic probiotics
evaluation of the effects of orange consumption on carbohydrate and lipid metabolism in subjects with mafld (metabolic associated fatty liver disease)

Conditions: Metabolic Disease; Fatty Liver, Nonalcoholic

Summary: given the current increase in the incidence of dyslipidemia and obesity in the general population, there is a strong interest in identifying dietary factors capable of preventing the onset of metabolic diseases or at least capable of reducing metabolic risk. several experimental evidences have shown that improving the carbohydrate and lipid profile in subjects at risk can reduce mortality linked to cardiovascular, neurodegenerative diseases and cancer. the diet is, therefore, an effective prevention tool in combating diseases related to metabolism, such as mafld (metabolic associated fatty liver disease). in particular, fruit with its high content of polyphenols has been shown to exert a high anti-inflammatory, antithrombotic and antiproliferative action. polyphenols extracted from oranges of the "tacle" variety have demonstrated in vitro an inhibitory action of cholesterol synthesis. in addition, the consumption of orange juice has been shown to improve the serum lipid profile of obese subjects, as well as "hesperedine", a flavonoid mainly present in oranges is able to reduce the proliferative activity of mcf-7 (human breast cancer cell line with estrogen, progesterone and glucocorticoid receptors) cells.


Eligibility criteria:
inclusion criteria: * age \> 30 years and \<65 years * diagnosis of mafld on the basis of clinical and instrumental parameters exclusion criteria: * gastroesophageal reflux diseases; * inflammatory bowel diseases; oncological diseases; * serious medical conditions that may impair participation in the trial; * people who follow a special diet or who use anticoagulants; * subjects unable to follow a diet for religious or other reasons.
effects of myofascial release with isometric exercises versus scapular stabilization exercise on neck pain in text neck

Conditions: Neck Pain

Summary: the objective of this study is to investigate the effects of myofascial release combined with isometrics and with scapular stabilization on neck pain, disability and rom in young adults with text neck syndrome

neck pain np (pain in cervical region) has been a major issue these days related to the increased use of smartphones. a posture that has been developed by growing use of technology is a posture called the text neck, which has become an epidemic to the world. the text neck is a posture in which a person keeps their head down (forward head posture) to look at their device for long periods of time. there are many medications and techniques used in management of neck pain. myofascial release has been proved to be efficacious for pain in the neck. this study is unique in that it examines the effect of myofascial therapy along with isometric exercises or scapular stabilization exercises on neck pain, disability, movements and daily life activities.

Eligibility criteria:
inclusion criteria: * young adults including both female and male between the ages of 18 to 26 years with neck pain who were using smart phone, tablet or laptop for past six-month duration and above. * subjects with average 3 or more than 3 hours mobile usage and who may have 3 out of the 6 possible symptoms for text neck which include pain in neck, upper back and shoulder pain, headache as well as insomnia, tingling and numbness in the hands for more than 6 months and with a complain of pain in neck after use of mobile phones or other gadgets. * individuals with ndi score of minimum 30%-48% i.e., moderate disability. * individuals with willingness to participate in this study. exclusion criteria: * specific causes of neck pain involving problems including neurological involvement such as myelopathy combined with weakness, sensory loss with numbness, cervical spinal stenosis and prolapse. * any previous neck or upper limb surgery. * any neurological disorders including headache and irradiated pain due to some diagnosed disease with involvement of infection and malignancy * cerebrovascular insufficiency, carcinoma or traumatic fractures or any chronic disease of musculoskeletal system such as polyarthritis. * individuals with acute pain and inflammation, torticollis, acute osteoarthritis, vertigo, heart disease, pregnancy will be excluded from this research.

Keywords: text neck syndrome pain and disability isometrics scapular stabilization myofascial release
tocilizumab in covid-19 pneumonia (tocivid-19)

Conditions: COVID-19 Pneumonia

Summary: this study project includes a single-arm phase 2 study and a parallel cohort study, enrolling patients with covid-19 pneumonia.

phase 2 study: this is a multicenter, single-arm, open-label, phase 2 study. all the patients enrolled are treated with tocilizumab. two-week (14 days) and one-month (30 days) lethality rates are the co-primary endpoints. the parallel cohort includes patients who are treated with tocilizumab and cannot enter the phase 2 study because: 1. emergency conditions or infrastructural or operational limits prevented registration before the administration of the experimental drug or 2. they had been intubated more than 24 hours before registration or 3. the phase 2 study has been closed due to reached sample size. this means that, after closure of the phase 2 enrolment, patients who might be eligible for the phase 2 study will be included in the observational cohort study. the same information planned for the phase 2 cohort is required also for the parallel cohort study whose sample size is not defined a priori, and that will close at the end of the overall project. all the patients enrolled are treated with tocilizumab. in both study groups (phase 2 and parallel cohort), participants receive one dose of tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). a second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the investigator.

Eligibility criteria:
inclusion criteria: 1. any gender 2. no age limit 3. informed consent for participation in the study (consent can be oral if a written consent cannot be expressed. if the subject is incapable of giving an informed consent and an authorized representative is not available without a delay that would, in the opinion of the investigator, compromise the potential life-saving effect of the treatment this can be administered without consent. consent to remain in the research should be sought as soon the conditions of the patient will allow it) 4. virological diagnosis of sars-cov-2 infection (real-time pcr) 5. hospitalized due to clinical/instrumental diagnosis of pneumonia 6. oxygen saturation at rest in ambient air ≤93% or requiring oxygen therapy or mechanical ventilation either non invasive or invasive (intubated) 7. patients with criteria #4 and #5 who have been already treated with tocilizumab before registration are eligible for the observational retrospective cohort exclusion criteria: 1. known hypersensitivity to tocilizumab or its excipients 2. known active infections or other clinical condition that contraindicate tocilizumab and cannot be treated or solved according to the judgement of the clinician 3. alt / ast\> 5 times the upper limit of the normality 4. neutrophils \<500 / mmc 5. platelets \<50.000 / mmc 6. bowel diverticulitis or perforation

Keywords: covid-19 pneumonia tocilizumab interleukin-6
influence of corneal biomechanical properties on myopia control

Conditions: Myopia

Summary: to analyze the changes in corneal biomechanics of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) and explore the possible mechanism of myopia control

high myopia is accompanied by excessive growth of eyeball, which leads to many complications. myopia control is a great concern of the government and ophthalmologists worldwide. atropine eye drops is used clinically to control the progression of myopia. in recent years, low dose atropine eye drops (0.01%, 0.05% and 0.1%) have been proven to be effective in slowing growth of eyeball. with less negative effects, these eye drops have been widely used for school children in taiwan. orthokeratology is another effective tool to control myopia, and long-term wearing of ortho-k lens can inhibit the speed of eyeball growth, it is the most useful optical treatment for myopia control. the corvis® st is a combination of an air pulse tonometer with an ultra-high-speed scheimpflug camera. the movement of the cornea is mainly influenced by three factors which can be measured by the instrument: intraocular pressure (iop)，biomechanical properties of the cornea and corneal thickness. the relationship between adult corneal biomechanics and refractive error has been noted in recent years. previous studies pointed out that corneal biomechanics analyzer (corvis st) can measure the deformation process of the cornea and the biomechanics parameters. these literature found that the corneas of myopic patients， esp. high myopic, have larger corneal deformation in biomechanics analysis and revealed that the corneal stiffness of myopia patients was lower. there are still few discussions about the effect of orthokeratology on corneal biomechanics and there is no research focused on the change of corneal biomechanics of low-concentration atropine user which is worthy of our further exploration. in this study, the investigators hope to analyze the changes in corneal biomechanics of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) and explore the possible mechanism of myopia control.

Eligibility criteria:
inclusion criteria: * myopia (\<-1d) * received orthokeratology or 0.01% atropine for myopia control * regular follow-up exclusion criteria: * ocular surface disease( dry eye, keratoconus..) * allergy to orthokeratology or atropine * received eye surgery * strabismus * premature birth
endocare for pelvic-perineal pain related to endometriosis used at home

Conditions: Endometriosis; Chronic Pain; Pelvic Pain

Summary: women with endometriosis experience recurrent pelvic-perineal pain impairing the quality of life, among other things. endometriosis-related pain negatively impacts the sexual, family and work life. apart from the usual painkillers, the doctor's current therapeutic arsenal is limited to hormonal contraceptives and surgery. as endometriosis-related treatments do not currently address all of the patients' problems, developing a new, effective, non-pharmaceutical treatment would make it possible to relieve the pain of these women. endocare treatment consists of visual and auditory therapeutic procedures for pelvic-perineal pain in patients with endometriosis. moreover, as endocare is not a pharmacological molecule but a digital therapy, it would not increase the consumption of pharmacological agents. an analgesic effect of endocare lasting several hours on chronic pelvic-perineal pain associated with endometriosis is expected. the effects of the treatment will be compare to a digital control also integrated in a virtual reality headset identical to the one distributing endocare allowing to maintain the blindness to the patients and the investigator on the treatment received.


Eligibility criteria:
inclusion criteria: * women over 18 years of age with diagnosed endometriosis (histology, imaging, clinical symptomatology) and/or adenomyosis. * women with at least 2 consecutive days per month of endometriosis-related pelvic-perineal pain of moderate to severe intensity (ns ≥ 4): * women without amenorrhea: pain around the onset of menstruation. * women with amenorrhea: most intense pain of the month. exclusion criteria: * pregnant or nursing women. * women participating, or who have participated, in a clinical interventional study within 30 days prior to inclusion. * women with severe visual, auditory or cognitive impairment, color blindness, photosensitivity, epilepsy or motion sickness. * women whose pain is occasional and not present at each menstrual period. * women who have previously received virtual reality treatments. * women under judicial protection, guardianship, curatorship, protective mandate.
study of actr087 in combination with sea-bcma in subjects with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma

Summary: this is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of actr087 (an autologous t cell product) in combination with sea-bcma (a monoclonal antibody) in subjects with relapsed or refractory multiple myeloma.


Eligibility criteria:
inclusion criteria: * signed written informed consent obtained prior to study procedures * histologically- or cytologically-confirmed relapsed or refractory multiple myeloma (mm) with measurable disease * must have received at least 3 prior lines of therapy to include treatment with a proteasome inhibitor (eg, bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (eg, lenalidomide, pomalidomide) unless double-refractory to both; and a hematopoietic stem cell transplant (hsct), for those subjects considered hsct-eligible. * quantitative serum igg levels for subjects with igg mm must not exceed the institutional upper limit of normal (uln) * ecog 0 or 1 * life expectancy of at least 6 months * absolute neutrophil (anc) count greater than 1000/ µl * platelet count greater than 50,000/µl * estimated gfr \>30ml/min/1.73m2 exclusion criteria: * known active central nervous system (cns) involvement by mm * systemic rheumatic or autoimmune diseases or acute or chronic infections * uncontrolled thromboembolic events or recent severe hemorrhage * subjects who are currently using more than 5mg/day of prednisone (or an equivalent glucocorticoid exceeding physiologic replacement levels) * prior treatment as follows: * t cell-directed antibody therapy (eg. alemtuzumab, anti-thymocyte globulin) within 6 months of enrollment * any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within 2 weeks of enrollment * any mab or other protein therapeutic containing fc-domains within 4 weeks of enrollment * experimental agents within 3 half-lives prior to enrollment, unless progression is documented on therapy * prior bcma-directed investigational agents at any time * prior cell or gene therapy, excluding transfers of genetically unmodified autologous cells (eg. hematopoietic stem cell transplantation), at any time; or prior allogeneic hsct at any time * pregnant or breastfeeding

Keywords: bcma sea-bcma b cell maturation antigen actr actr087 t cell t cell product relapsed refractory multiple myeloma adoptive t cells autologous gene therapy cell therapy
pattern of cell death following neoadjuvant therapy for metastatic colon cancer

Conditions: Metastatic Colorectal Cancer

Summary: systemic chemotherapy for metastatic colon cancer is often used in the neoadjuvant setting for patients undergoing liver resection. this treatment is given either to keep the tumor at bay or reduce its size before the time of resection. while many metastatic tumors might appear to respond well and even radiographically disappear following neoadjuvant therapy, it is unclear whether grossly or radiographically negative areas of previous disease are microscopically free of tumor cells. as such, when possible, resection boarders typically follow 1 cm margins from the tumor size prior to neoadjuvant therapy. these margins might be necessary to encompass all histologically present disease or they might be unnecessarily large, serving only to increase the mortality and morbidity of the operation. this study begins to address this question by a histological examination of the pattern of cell death in areas of metastases removed after neoadjuvant therapy. furthermore, clinical cases in which neoadjuvant therapy allowed for resection of previously unresectable cancer will be examined to determine whether there is an increased rate of recurrence despite "negative" resection boundaries in these cases.


Eligibility criteria:
inclusion criteria: * patients must be ≥ 18 years old. * patients must have colon cancer metastases to the liver. * patients must be candidates and be scheduled for liver resection. * patients must have received and have had a response to neoadjuvant therapy prior to liver resection. * patients must have signed institutional review board (irb) approved written consent form prior to registering in the study. exclusion criteria: * patients who are \< 18 years old. * patients who do not have colon cancer metastases to the liver. * patients who are not surgical candidates. * patients who do not schedule or who cancel a liver resection. * patients who have not received neoadjuvant therapy. * patients who have received neoadjuvant therapy but who have had no response or who have had tumor progression.

Keywords: metastatic colorectal cancer liver metastasis tumor margins neoadjuvant therapy